¿ªÔÆÌåÓý

Influenza-associated hospitalization rates by underlying conditions, 2016-17 to 2019-20: a retrospective cohort study. 

Journal of Infectious Diseases. 2025

Clinical epidemiology and risk factors for critical outcomes among vaccinated and unvaccinated adults hospitalized with COVID-19-VISION Network, 10 states, June 2021-March 2023. 

Clinical Infectious Diseases. 2024

Effectiveness of the original monovalent and bivalent COVID-19 vaccines against COVID-19-associated emergency department and urgent care encounters in pregnant persons who were not immunocompromised: VISION Network, June 2022-August 2023. 

Open forum infectious diseases. 2024

Influenza vaccine effectiveness against influenza A-associated emergency department, urgent care, and hospitalization encounters among US adults, 2022-2023. 

Journal of Infectious Diseases. 2024

Risk of COVID-19 hospitalization and protection associated with mRNA vaccination among US adults with psychiatric disorders. 

Influenza and other respiratory viruses. 2024

Vaccine effectiveness against pediatric influenza-A-associated urgent care, emergency department, and hospital encounters during the 2022-2023 season: VISION Network. 

Clinical Infectious Diseases. 2024

Effectiveness of BNT162b2 COVID-19 vaccination in children and adolescents. 

Pediatrics. 2023

Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: an observational study of real-world data across 10 US states from August-December 2021. 

Vaccine. 2023

Effectiveness of the original monovalent coronavirus disease 2019 vaccines in preventing emergency department or urgent care encounters and hospitalizations among adults with disabilities: VISION Network, June 2021-September 2022. 

Open forum infectious diseases. 2023

Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION Network, September 2022-April 2023. 

American Journal of Transplantation. 2023

Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA.4 and BA.5 sublineage periods. 

JAMA network open. 2023

Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design. 

Vaccine. 2023

Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort study. 

Lancet Reg Health Am. 2023

Protection of two and three mRNA vaccine doses against severe outcomes among adults hospitalized with COVID-19--VISION Network, August 2021 to March 2022. 

Journal of Infectious Diseases. 2023

Relationships between social vulnerability and coronavirus disease 2019 vaccination coverage and vaccine effectiveness. 

Clinical Infectious Diseases. 2023

Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network. 

Journal of Infectious Diseases. 2023

COVID-19 vaccination of people experiencing homelessness and incarceration in Minnesota. 

Health Affairs. 2022

Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION Network, nine states, September-November 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated - VISION Network, 10 states, December 2021-June 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of BNT162b2 and mRNA-1273 second doses and boosters for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and SARS-CoV-2-related hospitalizations: a statewide report from the Minnesota Electronic Health Record Consortium. 

Clinical Infectious Diseases. 2022

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years - VISION Network, 10 states, April 2021-January 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance - VISION Network, 10 states, December 2021-August 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during oeriods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad.26.COV2.S (Janssen (Johnson & Johnson)) vaccine dose against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults - VISION Network, 10 states, December 2021-March 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-nine states, January-September 2021. 

American Journal of Transplantation. 2022

Trends in COVID-19 vaccine administration and effectiveness through October 2021. 

JAMA network open. 2022

Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effect of clinical decision support on diagnostic imaging for pediatric appendicitis: a cluster randomized trial. 

JAMA network open. 2021

Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2021

Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity - nine states, January-September 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2021

Diagnostic performance of emergency physician gestalt for predicting acute appendicitis in patients age 5 to 20 years. 

Academic Emergency Medicine. 2020

Development of a clinical decision support system for pediatric abdominal pain in emergency department settings across two health systems within the HCSRN. 

EGEMS (Washington, DC). 2019

Text message alerts to emergency physicians identifying potential study candidates increase clinical trial enrollment. 

Journal of the American Medical Informatics Association. 2019

Validation of the Pediatric Appendicitis Risk Calculator (pARC) in a community emergency department setting. 

Annals of Emergency Medicine. 2019

Development and validation of a novel Pediatric Appendicitis Risk Calculator (pARC). 

Pediatrics. 2018

Implementation of electronic clinical decision support for pediatric appendicitis. 

Pediatrics. 2016

Effect of Hispanic ethnicity and language barriers on appendiceal perforation rates and imaging in children. 

Journal of Pediatrics. 2014

Development and validation of a risk equation for appendicitis in children presenting with abdominal pain [poster]

2017

Pediatric appendicitis: trends in emergency department imaging and outcomes in the community setting, 2010-2015 [abstract]. 

Annals of Emergency Medicine. 2016